This paper describes a marker-particle method designed to track fluid interfaces for fluid flows of at least three phases.
Mouritzen and colleagues [ 61] described a marker of type II collagen turnover, cartilage-derived urinary collagen type II C-telopeptide degradation products (CTX-II), in 615 healthy men and women from 20 to 87 years old.
Epidemiologic studies are generally ill-suited to describe a causal marker when multiple correlated markers, all with little if any known functional relevance to the phenotype in question, exist.
Christ-Crain and colleagues described a new marker in septic patients [ 19].
MiR-200a was found to be up-regulated in NAFLD [ 51], significantly down-regulated in human HCC samples and, along with miR-200 famembersmbers, has been described as a marker able to distinguish between cirrhotic and cancer tissues [ 52, 53].
FOXP3 (forkhead transcription factor 3) was initially described as a marker for regulatory T cells; however, its expression in several types of tumor cells has already been described and may have prognostic significance.
Here we present a proposed rectification of the current WHO classification of pituitary tumors describing an additional marker for TPA and specific threshold values for p53 and the mitotic index.
BTL has been recently described as a marker of transition from normal tissue to its neoplastic transformation in human kidney.
A decrease in circulating lymphocytes has been described as a marker of poor prognosis after septic shock; however, scarce data are available after cardiac arrest (CA).
CD57 has been described as a marker associated with terminal or near-terminal T-cell differentiation (Strioga et al., 2011; Focosi et al., 2010; Wu et al., 2012).
CD105 has been described as a marker of proliferation and adhesion [22].
